Glecaprevir/Pibrentasvir (Mavyret) coverage
Customize your policy alerts
Sign up for Peach State Health Plan Policy GA.PMN.24 alerts
Get alerted when Policy GA.PMN.24 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, approval criteria, dosing limits, contraindications, and treatment interruption guidance for Mavyret for Medicaid members. Affects prescribers and pharmacy/medical authorization staff processing prior authorization requests.
Added Appendix F for guidance on incomplete adherence and AASLD‑IDSA recommended management of treatment interruptions.
Removed qualifier of 'chronic' from HCV criteria to align with AASLD‑IDSA recommendation to treat both acute and chronic HCV.
Updated pediatric dosing and added oral pellet formulation for pediatric patients (age expansion to 3 years and older).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.